▁British 8.626835823059082
▁Bi 8.045157432556152
ote 1.8138556480407715
ch 0.12307390570640564
▁pl 7.982828617095947
c 0.21939852833747864
' 5.007468223571777
s 0.0024082427844405174
▁cancer 7.550723552703857
▁drug 1.0586084127426147
▁Mar 8.244661331176758
im 6.87927770614624
ast 0.004281374625861645
at 2.098105505865533e-05
▁Sh 8.635891914367676
ows 0.0489015057682991
▁Promise 1.9598761796951294
, 5.515429496765137
▁But 2.5026419162750244
▁F 3.9588592052459717
aces 2.0094516277313232
▁H 3.399867057800293
urd 0.02949386276304722
les 0.04105953127145767
▁to 3.2649967670440674
▁Be 5.000611782073975
come 1.1195604801177979
▁a 1.0431849956512451
▁Block 1.557130217552185
b 0.0015186271630227566
uster 0.0009582459460943937
<0x0A> 0.3201045095920563
B 3.4420864582061768
rit 0.095865897834301
ish 0.008978679776191711
▁Bi 0.037462856620550156
ote 0.000429066683864221
ch 0.009778830222785473
▁pl 0.3713269531726837
c 0.00017888954607769847
▁announced 4.450498104095459
▁prom 3.3411378860473633
ising 0.0010276350658386946
▁results 0.7039794921875
▁for 1.6026380062103271
▁its 0.37903812527656555
▁cancer 1.155484914779663
▁drug 0.10221315175294876
, 2.2806975841522217
▁Mar 0.17218035459518433
im 0.003147902199998498
ast 0.00021752101019956172
at 7.963497773744166e-05
, 0.4249168336391449
▁which 2.372357130050659
▁targets 4.505687713623047
▁the 1.3973652124404907
▁fast 10.341303825378418
- 0.6111993789672852
g 0.0329330638051033
row 0.0005993254599161446
ing 0.007559608202427626
▁matrix 7.593112945556641
▁metal 0.032102420926094055
lo 0.0026143959257751703
prote 0.025199558585882187
in 0.07330486178398132
ase 0.2355777472257614
▁( 0.9908692836761475
M 0.01488533616065979
MP 0.00047146464930847287
) 0.22272615134716034
▁market 3.6406280994415283
. 0.32383590936660767
▁The 1.7596700191497803
▁drug 1.3415439128875732
▁is 1.4286020994186401
▁designed 2.9986228942871094
▁to 0.056766726076602936
▁in 1.903562307357788
hib 0.002389780944213271
it 0.0008426877320744097
▁the 1.059805154800415
▁activity 1.9052950143814087
▁of 0.012510024011135101
▁specific 4.755959510803223
▁M 0.5011947154998779
MP 0.0006184105295687914
s 0.48033735156059265
▁that 1.9575610160827637
▁promote 3.4060306549072266
▁the 1.7108362913131714
▁growth 0.7436715364456177
▁and 1.4487996101379395
▁spread 0.6160192489624023
▁of 0.017912540584802628
▁cancer 0.6150066256523132
▁cells 0.9180598258972168
. 0.4184907376766205
▁The 2.0822198390960693
▁drug 1.7840685844421387
▁is 1.2876901626586914
▁currently 0.8589047193527222
▁in 0.6850765943527222
▁Ph 0.4752572774887085
ase 0.002054475713521242
▁III 0.5074442625045776
▁clin 0.8571807742118835
ical 0.0007127082208171487
▁tri 0.05301447585225105
als 0.00014449209265876561
, 1.7983527183532715
▁and 0.5240035057067871
▁results 3.4629390239715576
▁from 0.6174708604812622
▁a 2.1260719299316406
▁recent 2.668067455291748
▁trial 1.4879573583602905
▁demonstrate 4.394736289978027
▁the 2.302152395248413
▁drug 0.5602048635482788
' 0.21842069923877716
s 0.00021537477732636034
▁potential 1.1861636638641357
▁as 1.578752875328064
▁a 0.2774737775325775
▁th 3.6695573329925537
era 0.0007078768685460091
pe 0.0001914088352350518
ut 0.00024303766258526593
ic 0.0005025934078730643
▁option 2.239870309829712
▁for 0.2111835479736328
▁cancer 2.553234338760376
▁patients 0.08840401470661163
. 0.12468180805444717
<0x0A> 0.6365087628364563
Mar 1.7435771226882935
im 0.0027916620019823313
ast 0.0003698555810842663
at 0.00029061484383419156
▁has 2.0140836238861084
▁been 1.22514808177948
▁proven 4.616451263427734
▁to 0.35575297474861145
▁be 0.3490075170993805
▁effective 0.7027988433837891
▁against 2.6732895374298096
▁a 1.0716102123260498
▁wide 1.3996577262878418
▁range 0.10701441019773483
▁of 0.0005067678866907954
▁can 0.5662922263145447
cers 0.0001264890597667545
, 0.133756622672081
▁including 0.24389931559562683
▁pan 4.1361918449401855
cre 0.0001403191708959639
atic 0.02452019415795803
▁cancer 1.799940824508667
, 0.12108860164880753
▁col 1.6481605768203735
ore 0.001434818492271006
ct 0.00025066896341741085
al 0.00026163901202380657
▁cancer 0.009183424524962902
, 0.02365976572036743
▁and 0.6918365955352783
▁met 4.1513776779174805
ast 0.002519321395084262
atic 0.01540969405323267
▁mel 2.0510923862457275
an 0.0001540302619105205
oma 0.004126946907490492
. 0.12447351962327957
▁The 0.8121489882469177
▁drug 0.1628044843673706
▁in 4.385838985443115
hib 0.0019103046506643295
its 0.002530137076973915
▁the 0.2697077691555023
▁activity 0.661701500415802
▁of 0.0005097496323287487
▁M 0.4460723102092743
MP 0.0010457736207172275
s 0.49761277437210083
, 0.33744168281555176
▁which 0.11560001969337463
▁play 2.2824504375457764
▁critical 7.698273181915283
▁roles 0.004765702411532402
▁in 0.0007248762995004654
▁many 5.074429512023926
▁phys 3.132338523864746
i 0.002027001464739442
ological 0.01788019761443138
▁processes 0.26488250494003296
, 0.4715920090675354
▁such 1.843721628189087
▁as 0.0001251775975106284
▁t 1.6801337003707886
issue 0.0002419645170448348
▁rem 0.45012688636779785
od 0.0020200135186314583
eling 0.0703640952706337
, 0.762120246887207
▁w 1.1140376329421997
ound 6.532882252940908e-05
▁he 0.07408791035413742
aling 9.298368240706623e-06
, 0.015596689656376839
▁and 0.06347084790468216
▁tum 2.2409489154815674
or 0.020047422498464584
▁invasion 0.9399015307426453
. 0.6421007513999939
▁When 3.505976676940918
▁M 0.6935427188873291
MP 0.00030379139934666455
s 0.15266066789627075
▁are 0.2357788234949112
▁over 0.48221445083618164
activ 2.3918590545654297
ated 0.0010584827978163958
, 0.1586645245552063
▁as 3.9092864990234375
▁in 1.1686608791351318
▁cancer 1.2368450164794922
, 1.2874689102172852
▁they 0.10832257568836212
▁promote 1.7109453678131104
▁the 0.5192596316337585
▁growth 0.13047397136688232
▁and 0.08370078355073929
▁spread 0.06406974047422409
▁of 0.0008118467521853745
▁cancer 0.2177964150905609
▁cells 0.014354179613292217
▁by 3.063694477081299
▁de 0.6589380502700806
grad 0.0013488683616742492
ing 0.0003281177778262645
▁the 0.2918662130832672
▁ext 0.16857290267944336
rac 5.245222382654902e-06
ell 3.230623769923113e-05
ular 0.0006529435631819069
▁matrix 0.001706804265268147
▁( 1.931859016418457
EC 0.005436269100755453
M 6.127545202616602e-05
) 1.703162670135498
▁surrounding 3.163858413696289
▁the 1.127938985824585
▁tum 0.966630220413208
or 0.10028401017189026
. 0.44496309757232666
<0x0A> 1.0494948625564575
The 0.960716724395752
▁Ph 1.7750344276428223
ase 0.00044278171844780445
▁III 0.026482125744223595
▁clin 1.267497181892395
ical 8.142326259985566e-05
▁trial 0.5960162878036499
▁conducted 3.8506925106048584
▁by 0.15541420876979828
▁British 0.10023076832294464
▁Bi 0.0028944737277925014
ote 7.689295307500288e-05
ch 0.0016739662969484925
▁pl 1.578883171081543
c 3.540578472893685e-05
▁demonstrated 2.1934468746185303
▁that 0.6908860802650452
▁Mar 0.138046532869339
im 0.0008186471532098949
ast 9.572964336257428e-05
at 8.809955033939332e-05
▁can 3.139223337173462
▁significantly 1.061921238899231
▁improve 1.2892791032791138
▁the 0.9808470010757446
▁pro 1.8311067819595337
gression 0.2536814212799072
- 0.012041477486491203
free 0.00030104874167591333
▁surv 0.018401876091957092
ival 8.011185127543285e-05
▁rate 2.069103240966797
▁of 0.6111236810684204
▁patients 0.5465446710586548
▁with 0.060717083513736725
▁advanced 1.186526894569397
▁pan 0.8624736070632935
cre 0.00010598267544992268
atic 0.001973249949514866
▁cancer 0.017897794023156166
. 0.3893759548664093
▁In 2.135148286819458
▁the 0.45631545782089233
▁trial 0.23210769891738892
, 0.0036463977303355932
▁patients 1.1707262992858887
▁who 1.1390875577926636
▁received 0.05180578678846359
▁Mar 0.10793247073888779
im 0.0004318096616771072
ast 0.00015486485790461302
at 8.857642387738451e-05
▁had 0.8641226887702942
▁a 0.10492929816246033
▁median 1.2134952545166016
▁pro 0.056483764201402664
gression 2.7180087272427045e-05
- 0.0029436121694743633
free 0.00035554528585635126
▁surv 0.000517919659614563
ival 1.8716033082455397e-05
▁rate 1.4554381370544434
▁of 0.007063781842589378
▁ 0.04879792034626007
2 2.213477611541748
. 0.7094141244888306
3 2.5919437408447266
▁months 0.04520241916179657
, 0.2274358570575714
▁compared 0.28867900371551514
▁to 0.05848432704806328
▁ 0.3547963798046112
1 0.15644124150276184
. 0.009110881015658379
6 1.941817283630371
▁months 0.00374463084153831
▁for 0.6445223689079285
▁patients 0.5783625245094299
▁who 0.14955748617649078
▁received 0.03340195119380951
▁the 1.3391025066375732
▁place 0.7016375064849854
bo 6.258683424675837e-05
. 0.021417047828435898
▁The 1.0960344076156616
▁drug 1.3222180604934692
▁showed 4.428305149078369
▁similar 2.240323543548584
▁prom 3.7115602493286133
ising 0.00022956382599659264
▁results 0.02529100701212883
▁in 0.1098087802529335
▁the 2.694901704788208
▁treatment 0.476010799407959
▁of 0.0005760659696534276
▁other 2.704280138015747
▁can 0.6268507242202759
cers 3.683635077322833e-05
▁as 2.76554274559021
▁well 0.0012552269035950303
. 0.48009735345840454
<0x0A> 0.10803168267011642
However 1.4838052988052368
, 9.66834049904719e-05
▁despite 1.3454116582870483
▁Mar 4.406485557556152
im 0.0007038208423182368
ast 5.042680277256295e-05
at 0.0003415929386392236
' 0.010729929432272911
s 0.0004929326823912561
▁potential 0.8693702220916748
▁to 1.9452122449874878
▁become 0.6326603293418884
▁a 0.017294321209192276
▁block 0.20625604689121246
b 4.816171349375509e-05
uster 6.509038939839229e-05
▁drug 0.2857171297073364
, 0.1392548680305481
▁there 1.3649219274520874
▁are 0.008466399274766445
▁significant 2.6253271102905273
▁hur 0.8032577037811279
d 1.6689314179529902e-06
les 2.2411597456084564e-05
▁that 0.5044209957122803
▁British 0.6415928602218628
▁Bi 0.0011170783545821905
ote 7.391003236989491e-06
ch 0.00022574827016796917
▁pl 0.0255751870572567
c 1.3709161976294126e-05
▁will 0.8584975600242615
▁have 1.3214924335479736
▁to 1.5139694369281642e-05
▁overcome 0.026650944724678993
. 1.253145456314087
▁First 2.033201217651367
ly 0.8254975080490112
, 8.857642387738451e-05
▁the 0.2690460979938507
▁drug 0.8177171349525452
' 1.6237603425979614
s 3.95782662963029e-05
▁pat 1.5725934505462646
ent 0.08049358427524567
▁protection 0.9757786989212036
▁has 3.7224972248077393
▁exp 0.4915538430213928
ired 5.0665232265600935e-05
, 0.3454229235649109
▁which 0.9092230796813965
▁means 0.4963139295578003
▁that 0.15838152170181274
▁the 3.196099281311035
▁drug 1.845298171043396
▁is 1.5473449230194092
▁now 1.0197428464889526
▁available 0.5823692083358765
▁as 0.7678107023239136
▁a 0.019842935726046562
▁generic 0.023733556270599365
▁drug 1.163949966430664
. 0.35817191004753113
▁This 0.4638272821903229
▁will 1.5192601680755615
▁make 0.8514828681945801
▁it 0.024285780265927315
▁difficult 0.3000447750091553
▁for 0.0804959088563919
▁British 0.5295221209526062
▁Bi 0.0009676129557192326
ote 4.0651193558005616e-05
ch 5.3884050430497155e-05
▁pl 0.0556928813457489
c 5.93679906160105e-05
▁to 0.0009407055913470685
▁generate 2.28940749168396
▁significant 0.36250507831573486
▁re 0.7158650159835815
venue 2.8252999982214533e-05
▁from 0.038330916315317154
▁the 0.2998316287994385
▁drug 0.20522429049015045
. 0.31920990347862244
<0x0A> 0.5083959698677063
Second 0.5264971256256104
ly 0.0003912617976311594
, 2.8252999982214533e-05
▁the 0.4490138292312622
▁company 1.8995250463485718
▁will 0.5977559089660645
▁need 2.047900915145874
▁to 0.0024742071982473135
▁demonstrate 1.4354639053344727
▁the 0.47979432344436646
▁drug 0.7444194555282593
' 0.0006166213424876332
s 4.7565637942170724e-05
▁safety 1.169596791267395
▁and 0.014635569415986538
▁effic 0.0687585175037384
acy 1.2397842510836199e-05
▁through 4.804210186004639
▁further 1.8967454433441162
▁clin 0.026277480646967888
ical 1.2636264727916569e-05
▁tri 0.004784448072314262
als 3.576279254957626e-07
. 0.5122042894363403
▁While 2.509291648864746
▁the 0.10520273447036743
▁results 1.4494067430496216
▁from 1.1516445875167847
▁the 0.03679446876049042
▁Ph 0.12386669963598251
ase 1.8835246009984985e-05
▁III 0.0010310957441106439
▁clin 0.6762704253196716
ical 3.707477662828751e-05
▁trial 0.08491870015859604
▁are 0.6276094317436218
▁prom 0.1968117207288742
ising 1.4186005500960164e-05
, 0.0004029489355161786
▁they 2.7453508377075195
▁will 2.2921886444091797
▁need 0.17952071130275726
▁to 0.00025484233628958464
▁be 0.000599563994910568
▁rep 0.7174123525619507
licated 0.00025555776664987206
▁in 0.11900994926691055
▁larger 0.37178704142570496
- 4.499920845031738
scale 0.0017250149976462126
▁tri 0.8523788452148438
als 2.3841860752327193e-07
▁to 0.6837772727012634
▁ensure 2.9354023933410645
▁that 0.7338320016860962
▁the 0.06260684132575989
▁drug 0.016849471256136894
▁is 0.22783394157886505
▁safe 0.22471967339515686
▁and 0.04552699625492096
▁effective 0.005169618409126997
▁for 0.25149258971214294
▁a 1.0710585117340088
▁wider 0.7516806125640869
▁range 0.5169163942337036
▁of 3.910141094820574e-05
▁patients 0.8688133358955383
. 0.024895748123526573
<0x0A> 0.06601157039403915
Th 1.2451462745666504
ird 0.00021990570530761033
ly 0.00039269289118237793
, 8.261545008281246e-05
▁Mar 3.0318193435668945
im 0.00048207936924882233
ast 7.105126132955775e-05
at 6.17523182881996e-05
▁faces 1.75664222240448
▁competition 0.861514687538147
▁from 0.004816729575395584
▁other 0.03353951498866081
▁M 0.5261511206626892
MP 0.00018723572429735214
▁in 0.05156394839286804
hib 3.337865791763761e-06
itors 0.011082079261541367
▁currently 3.7380530834198
▁in 0.35481929779052734
▁development 0.31035828590393066
. 0.2649115324020386
▁Several 2.8849551677703857
▁other 1.2523187398910522
▁ph 2.1800150871276855
arma 8.535749657312408e-05
ce 0.0024589109234511852
ut 1.4305124977909145e-06
ical 2.861027041944908e-06
▁companies 0.0015104489866644144
▁are 0.6849123239517212
▁developing 0.5858215093612671
▁M 0.46344056725502014
MP 9.155692532658577e-05
▁in 0.004963716492056847
hib 1.9073504518019035e-06
itors 0.0062728761695325375
▁to 3.3868911266326904
▁target 2.834176540374756
▁cancer 2.6283185482025146
, 1.0721477270126343
▁such 4.263613700866699
▁as 5.352640073397197e-05
▁Gla 3.2384567260742188
x 0.000843880872707814
o 0.0013526881812140346
Smith 0.00593920424580574
K 0.0005769009003415704
line 0.000371644418919459
▁pl 0.3876764178276062
c 5.614915062324144e-05
' 1.8189964294433594
s 0.00025722713326103985
▁B 4.18673849105835
MS 1.5831618309020996
- 0.05577663704752922
2 0.8046112656593323
7 0.08840661495923996
5 0.028897833079099655
2 0.04598909616470337
9 5.436091305455193e-05
1 0.001039090915583074
▁and 0.38656970858573914
▁Mill 4.814947605133057
en 0.19443157315254211
ni 0.00031011144164949656
um 0.00030868049361743033
▁Ph 0.029698554426431656
arma 0.013984314166009426
ce 0.00047015270683914423
ut 0.0003999675391241908
ical 0.0006145935039967299
s 0.04379960149526596
▁Inc 0.7379377484321594
.' 0.16743162274360657
s 0.0005418934742920101
▁( 6.958629131317139
now 1.9108866453170776
▁Tak 2.140871047973633
eda 0.0005784514942206442
▁Ph 0.05612226203083992
arma 0.003233349649235606
ce 0.00648456672206521
ut 0.0004931712173856795
ical 0.0002871567849069834
▁Co 1.4975088834762573
. 0.8292577266693115
▁Ltd 0.01719856821000576
.) 0.44488897919654846
▁Prin 12.30706787109375
om 4.05731725692749
ast 0.00014449209265876561
at 6.592490535695106e-05
. 0.023207683116197586
▁This 3.816951274871826
▁means 2.2306580543518066
▁that 0.001709789619781077
▁British 0.26780179142951965
▁Bi 0.0010986400302499533
ote 1.5378116586362012e-05
ch 5.7102879509329796e-05
▁pl 0.0042257062159478664
c 3.7909270758973435e-05
▁will 0.011666977778077126
▁need 0.5420730710029602
▁to 0.0001574878697283566
▁work 4.1766157150268555
▁hard 0.31041041016578674
▁to 0.00227142870426178
▁differenti 0.13382606208324432
ate 2.9802365588693647e-06
▁Mar 0.5701050162315369
im 0.0006376749370247126
ast 6.17523182881996e-05
at 5.5314641940640286e-05
▁from 0.03761466220021248
▁its 0.9515988826751709
▁compet 0.03193581849336624
itors 0.0014391163131222129
▁and 0.44446998834609985
▁position 3.797483444213867
▁it 0.2648618817329407
▁as 0.008522424846887589
▁the 0.784262478351593
▁most 3.553149461746216
▁effective 0.117897167801857
▁M 1.1043400764465332
MP 0.00010347901843488216
▁in 0.0010469669941812754
hib 3.337865791763761e-06
itor 0.0003185779496561736
. 2.72489070892334
<0x0A> 0.008462191559374332
B 4.134699821472168
rit 0.07963947206735611
ish 0.00021537477732636034
▁Bi 0.0024674551095813513
ote 0.00043049780651926994
ch 0.0004413505957927555
▁pl 0.012437962926924229
c 3.2902302336879075e-05
▁will 2.3361940383911133
▁need 1.0294291973114014
▁to 0.005822949111461639
▁invest 2.7064435482025146
▁in 3.981297254562378
▁market 2.648362159729004
ing 0.0016891909763216972
▁and 0.03716228902339935
▁research 4.07084321975708
▁and 0.29245778918266296
▁development 0.00020178208069410175
▁to 0.2926850914955139
▁ensure 0.9591296911239624
▁that 0.09834983944892883
▁Mar 0.08826826512813568
im 0.0007150940946303308
ast 5.769896233687177e-05
at 6.89053485984914e-05
▁becomes 2.5087292194366455
▁a 0.01408961322158575
▁block 0.24548473954200745
b 4.6373490476980805e-05
uster 3.361758354003541e-05
▁drug 0.01587352342903614
. 0.049605660140514374
▁The 0.274446576833725
▁company 0.03192566707730293
▁will 0.21095257997512817
▁need 0.7782771587371826
▁to 0.0005943157011643052
▁conduct 2.25184965133667
▁further 1.2147061824798584
▁tri 4.2508416175842285
als 2.861027041944908e-06
▁to 0.19601790606975555
▁demonstrate 0.21976949274539948
▁the 0.019388442859053612
▁drug 0.02451530657708645
' 0.0003618656483013183
s 2.1457903130794875e-05
▁safety 0.32613614201545715
▁and 0.004314298275858164
▁effic 0.004614073783159256
acy 9.179157132166438e-06
▁and 1.4069584608078003
▁to 1.5673080682754517
▁determine 3.652662754058838
▁the 0.9089550971984863
▁optimal 0.4386296570301056
▁do 1.702224612236023
se 4.053124484926229e-06
▁and 0.33595699071884155
▁treatment 1.7980681657791138
▁for 8.396860122680664
▁each 3.040968894958496
▁cancer 1.017378807067871
▁type 0.08509967476129532
. 0.004550124052911997
▁Additionally 1.9876079559326172
, 5.078444519313052e-05
▁the 0.2529350519180298
▁company 0.007516428362578154
▁will 0.017197174951434135
▁need 0.005894175730645657
▁to 0.00022753680241294205
▁develop 1.6257665157318115
▁strong 5.521465301513672
▁partners 1.1986734867095947
hips 0.0010318116983398795
▁with 0.034985531121492386
▁phys 4.829525947570801
icians 0.00546233868226409
, 1.1314992904663086
▁hosp 1.2282614707946777
it 5.602852525044e-06
als 2.3841860752327193e-07
, 0.003749596420675516
▁and 0.0050285919569432735
▁other 1.2207105159759521
▁st 1.7579894065856934
ake 7.152559646783629e-07
hold 9.811405470827594e-05
ers 1.1920930376163597e-07
▁to 0.1314910352230072
▁ensure 0.49500828981399536
▁that 0.029937250539660454
▁Mar 0.6348094940185547
im 0.0010181482648476958
ast 4.100883597857319e-05
at 6.19907514192164e-05
▁is 0.1605415642261505
▁widely 0.4162278175354004
▁pres 3.1924245357513428
cribed 0.00018449340132065117
▁and 0.30918440222740173
▁used 0.32721561193466187
▁in 2.3757731914520264
▁the 1.0453736782073975
▁treatment 0.2189650535583496
▁of 0.000273324636509642
▁cancer 0.019878076389431953
. 0.07950064539909363
<0x0A> 0.025379346683621407
Des 2.292419910430908
p 6.544803909491748e-05
ite 3.1233324989443645e-05
▁the 0.7613142728805542
▁challeng 0.24339377880096436
es 0.00012768131273332983
, 0.6232927441596985
▁Mar 1.5623162984848022
im 0.0005474992794916034
ast 3.206781548215076e-05
at 2.4080563889583573e-05
' 2.7180840969085693
s 2.6703237381298095e-05
▁potential 0.11637444794178009
▁to 0.7511402368545532
▁become 0.04820241406559944
▁a 0.0013245171867311
▁block 0.018478376790881157
b 2.8729851692332886e-05
uster 1.430521751899505e-05
▁drug 0.01717340387403965
▁is 0.3274412453174591
▁significant 0.32787755131721497
. 0.04703519493341446
▁The 0.38704267144203186
▁drug 0.04575851932168007
▁has 0.967972993850708
▁demonstrated 1.5551984310150146
▁prom 0.3768537640571594
ising 1.6927862816373818e-05
▁results 0.016895847395062447
▁in 0.01473029050976038
▁Ph 2.878129005432129
ase 3.278309304732829e-05
▁III 0.013016832061111927
▁clin 0.043533291667699814
ical 5.483642780745868e-06
▁tri 0.00040151787106879056
als 1.1920930376163597e-07
▁and 1.1061227321624756
▁has 0.3143419027328491
▁the 0.5211859941482544
▁potential 0.019077401608228683
▁to 9.930626401910558e-05
▁become 1.9189393520355225
▁a 0.19606299698352814
▁valuable 3.3124265670776367
▁th 0.6859164237976074
era 1.4305124977909145e-06
pe 4.768382950715022e-06
ut 3.49289330188185e-05
ic 6.198902156029362e-06
▁option 0.0023225077893584967
▁for 0.010977216064929962
▁cancer 0.14240707457065582
▁patients 0.0003801114216912538
. 0.05658121034502983
▁British 0.896518349647522
▁Bi 0.0006362434942275286
ote 1.811997572076507e-05
ch 9.680262883193791e-05
▁pl 0.0006265814881771803
c 2.098105505865533e-05
▁must 5.338851451873779
▁work 1.2282859086990356
▁hard 0.12740296125411987
▁to 0.0023014184553176165
▁overcome 0.6024655103683472
▁the 0.04247623309493065
▁hur 0.6289581060409546
d 3.218656047465629e-06
les 4.232019273331389e-05
▁and 0.7011545896530151
▁position 0.8287116289138794
▁Mar 0.1429852396249771
im 0.00043622232624329627
ast 1.0490472050150856e-05
at 8.118482219288126e-05
▁as 0.002090910216793418
▁the 0.07656112313270569
▁most 1.2650855779647827
▁effective 0.00226993509568274
▁M 0.0361708328127861
MP 0.00012553526903502643
▁in 0.0006134007126092911
hib 2.741817297646776e-06
itor 7.832357368897647e-05
▁on 0.8600471019744873
▁the 4.232019273331389e-05
▁market 0.00011921639816137031
. 0.016957316547632217
▁With 1.1625213623046875
▁the 0.6072518825531006
▁right 0.052368275821208954
▁invest 0.6479130983352661
ment 0.37613749504089355
▁and 0.5035851001739502
▁strategy 2.20558762550354
, 0.0210734773427248
▁Mar 0.2051062434911728
im 0.0005513161304406822
ast 3.862455560010858e-05
at 4.661191633203998e-05
▁could 1.1099194288253784
▁become 0.10014953464269638
▁a 0.06233161315321922
▁key 4.54386043548584
▁player 0.25181177258491516
▁in 0.000220859597902745
▁the 0.004059437196701765
▁fight 0.8731686472892761
▁against 6.032171950209886e-05
▁cancer 0.000494125357363373
. 0.21595162153244019
